Atria Investments Inc Decreases Stake in Cencora, Inc. $COR

Atria Investments Inc lessened its position in shares of Cencora, Inc. (NYSE:COR) by 7.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,761 shares of the company’s stock after selling 3,693 shares during the period. Atria Investments Inc’s holdings in Cencora were worth $15,239,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its holdings in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its position in shares of Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Cloud Capital Management LLC purchased a new position in shares of Cencora in the 3rd quarter valued at about $31,000. Westside Investment Management Inc. raised its position in shares of Cencora by 200.0% during the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after acquiring an additional 70 shares in the last quarter. Finally, Copia Wealth Management lifted its stake in Cencora by 505.0% during the third quarter. Copia Wealth Management now owns 121 shares of the company’s stock worth $38,000 after purchasing an additional 101 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

COR has been the topic of a number of research analyst reports. Mizuho raised their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Barclays initiated coverage on shares of Cencora in a research report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target for the company. Bank of America dropped their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. Finally, UBS Group boosted their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $396.92.

Insiders Place Their Bets

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 20,316 shares of company stock worth $7,151,265. 0.38% of the stock is owned by corporate insiders.

Cencora Stock Up 1.6%

COR stock opened at $365.89 on Thursday. The stock has a market capitalization of $70.98 billion, a PE ratio of 43.98, a price-to-earnings-growth ratio of 1.66 and a beta of 0.68. The company has a fifty day moving average of $346.79 and a 200-day moving average of $327.66. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a one year low of $237.71 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.73 earnings per share. As a group, analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.